InsiderTrades

Form 4 for MRNA Moderna

Accepted 2023-03-02 00:00:00 ET · period of report 2023-02-28 · accession 0001127602-23-008449 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2023-03-02 2023-02-28 MRNA Hoge Stephen Pres M - OptEx $0.00 +2,410 1.63M +0.1% $0
D 2023-03-02 2023-03-01 MRNA Hoge Stephen Pres S - Sale+OE $138.03 -1,072 1.63M -0.1% -$148.0K
DM 2023-03-02 2023-02-28 MRNA Hoge Stephen Pres A - Grant $0.00 +47.0K 9,768 New $0
D 2023-03-02 2023-02-28 MRNA Hoge Stephen Pres M - OptEx $0.00 -2,410 9,643 -20% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-02-28 M A 2,410 $0.00 1,630,103 D — —
2 Common Common Stock 2023-03-01 S D 1,072 $138.03 1,629,031 D — —
3 Derivative Stock Option (Right to Buy) 2023-02-28 A A 37,217 $0.00 37,217 D $138.81 · 2024-02-28 to 2033-02-28 37,217 Common Stock (F5) 25% of this option will vest and become exercisable on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
4 Derivative Restricted Stock Units 2023-02-28 A A 9,768 $0.00 9,768 D $0.00 · — to — 9,768 Common Stock (F6) 25% of the shares subject to this restricted stock unit award will vest on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
5 Derivative Restricted Stock Units 2023-02-28 M D 2,410 $0.00 9,643 D $0.00 · 2022-02-28 to — 2,410 Common Stock (F4) 50% of the shares subject to this restricted stock unit award vested on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter.